Pfizer Global Medical Grants RFP – Atopic Dermatitis and Alopecia Areata

Well-being, Health and Biomedical Discovery


Academic Unit: inquire with unit

Memorial Deadline: Wednesday 6th, July 2022

External Deadline: Tuesday 12th, July 2022


Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP.

For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

Date RFP Issued: April 7, 2022

Geographic Scope: Canada

Clinical Area: Atopic Dermatitis and Alopecia Areata

Link to full RFP: Atopic Dermatitis and Alopecia Areata

Application Due Date: May 25, 2022 Deadline Extended: June 21, 2022  Deadline Further Extended: July 12, 2022 

Specific Area of Interest: Quality improvement (QI) Projects that will be considered for Pfizer support will focus on improving access to care for patients affected by Atopic Dermatitis (AD) / Alopecia Areata (AA) through the implementation of innovative solutions aimed at:

  • – Improving the referral and flow process of patients with AD and AA to medical centers
  • – Supporting collaboration among health care providers within a multidisciplinary team environment to improve the management of patients with AD or AA
  • – Improving treatment adherence of patients with AD or AA
  • – Implementing health care technologies (mobile or web-based tools) for telehealth and remote monitoring

Identifying and addressing mental health issues and challenges for patients with AD or AA

Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Beth Brillinger, Grant Officer (

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: June 21, 2022